Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.

MLA

Catenacci, Daniel V. T., et al. “Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 38, no. 21, July 2020, pp. 2418–26. EBSCOhost, https://doi.org/10.1200/JCO.19.01834.

APA

Catenacci, D. V. T., Rasco, D., Lee, J., Rha, S. Y., Lee, K.-W., Bang, Y. J., Bendell, J., Enzinger, P., Marina, N., Xiang, H., Deng, W., Powers, J., & Wainberg, Z. A. (2020). Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 38(21), 2418–2426. https://doi.org/10.1200/JCO.19.01834

Chicago

Catenacci, Daniel V T, Drew Rasco, Jeeyun Lee, Sun Young Rha, Keun-Wook Lee, Yung Jue Bang, Johanna Bendell, et al. 2020. “Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 38 (21): 2418–26. doi:10.1200/JCO.19.01834.